ocrelizumab
Selected indexed studies
- Ocrelizumab: A Review in Multiple Sclerosis. (Drugs, 2022) [PMID:35192158]
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (N Engl J Med, 2017) [PMID:28002679]
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. (N Engl J Med, 2017) [PMID:28002688]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ocrelizumab: A Review in Multiple Sclerosis. (2022) pubmed
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (2017) pubmed
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. (2017) pubmed
- Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. (2023) pubmed
- Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. (2023) pubmed
- Ocrelizumab for multiple sclerosis. (2022) pubmed
- Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. (2024) pubmed
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. (2011) pubmed
- Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. (2025) pubmed
- [Ocrelizumab for treatment of multiple sclerosis]. (2020) pubmed